文献速递衰弱、肌少症与跌倒老年慢病共病管理

≥80岁房颤患者口服抗凝的长期临床结局:GLORIA-AF注册研究III期报告

Long-term clinical outcomes of oral anticoagulation in the older patients with atrial fibrillation aged ≥80 years: a report from the GLORIA-AF registry phase III.
PubMed 文献 · Age Ageing · 2025-01-01

基于GLORIA-AF前瞻性多中心注册研究,分析≥75岁房颤患者中≥80岁人群的3年结局。多变量校正后,高龄与全因死亡、心血管死亡、MACE、血栓栓塞、大出血、卒中和心肌梗死风险升高独立相关;在≥80岁患者中,与VKA相比,NOAC使用与较低的全因死亡、心血管死亡、MACE和大出血风险相关,且在衰弱患者中NOACs对死亡、MACE和大出血的获益更明显。

要点

  • ≥80岁房颤患者较高龄以下人群的死亡、大出血、血栓栓塞和MACE风险显著升高。
  • ≥80岁患者中NOAC较VKA降低全因死亡、心血管死亡、MACE和大出血风险。
  • 衰弱患者中NOACs对死亡、MACE和大出血的获益优于华法林。

核心结论

  • 高龄(≥80岁)与房颤患者全因死亡、心血管死亡、MACE、血栓栓塞、大出血、卒中和心肌梗死风险升高独立相关。
  • 在≥80岁患者中,与VKA相比,NOAC使用与较低的全因死亡、心血管死亡、MACE和大出血风险相关。
  • NOACs对死亡、MACE和大出血的获益在衰弱患者中更明显,且NOACs与华法林的有效性和安全性在不同地区一致。

研究设计与样本

  • 研究为前瞻性、多中心GLORIA-AF注册研究III期分析,按年龄分析≥75岁患者3年随访结局。
  • 共纳入7652例≥75岁患者(年龄80.1±3.9岁,47.1%男性),其中4006例≥80岁(年龄83.4±3.9岁,43.5%男性)。

主要发现

  • 多变量校正后,较高龄患者全因死亡风险升高(HR 1.94,95%CI 1.67-2.27)。
  • 较高龄患者心血管死亡风险升高(HR 2.17,95%CI 1.71-2.74),MACE风险升高(HR 1.57,95%CI 1.32-1.86)。
  • 较高龄患者血栓栓塞风险升高(HR 1.45,95%CI 1.14-1.83),大出血风险升高(HR 1.30,95%CI 1.04-1.63)。
  • 较高龄患者卒中风险升高(HR 1.38,95%CI 1.06-1.80),心肌梗死风险升高(HR 1.59,95%CI 1.14-2.22)。
  • 在≥80岁患者中,与VKA相比,NOAC使用与较低的全因死亡(HR 0.79,95%CI 0.65-0.97)、心血管死亡(HR 0.70,95%CI 0.51-0.96)、MACE(HR 0.72,95%CI 0.56-0.92)和大出血(HR 0.66,95%CI 0.48-0.92)风险相关。

关键数值与推荐

  • 高龄相关临床事件风险主要在歐洲和亚洲观察到(p-interaction > 0.05),但NOACs与华法林的有效性和安全性在不同地区一致。

临床怎么用

  • 对≥80岁房颤患者应重视血栓栓塞和出血风险评估,并考虑口服抗凝治疗。
  • 在≥80岁患者中,NOACs可作为VKA的替代选择,尤其对衰弱患者可能获益更多。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Older age increases the risk of thromboembolism (TE) and major bleeding in atrial fibrillation (AF) patients, but limited evidence exists regarding the older population (age ≥ 80) especially from different global regions. Data on benefits of oral anticoagulants in these very old individuals are also limited. METHODS: From the prospective, multicenter Global Registry on Long-Term Antithrombotic Treatment in Patients with Atrial Fibrillation registry, we analysed by age all-cause death, cardiovascular death, major adverse cardiovascular events (MACE), TE, major bleeding, stroke, and myocardial infarction (MI) over 3-years follow-up. RESULTS: Of 7652 patients aged ≥75 years (age 80.1 ± 3.9 years, 47.1% male), 4006 were ≥ 80 years (age 83.4 ± 3.9 years, 43.5% male). After multivariable adjustment, older patients had a higher risk of all-cause death (HR:1.94, 95% CI: 1.67-2.27), cardiovascular death (HR: 2.17, 95% CI: 1.71-2.74), MACE (HR: 1.57, 95% CI: 1.32-1.86), TE (HR: 1.45, 95% CI: 1.14-1.83), major bleeding (HR: 1.30, 95% CI: 1.04-1.63), stroke (HR: 1.38, 95% CI: 1.06-1.80) and MI (HR: 1.59, 95% CI:1.14-2.22). Compared with VKA, NOAC use in patients ≥80 years was associated with lower risks of all-cause death (HR: 0.79, 95% CI: 0.65-0.97), cardiovascular death (HR: 0.70, 95% CI: 0.51-0.96), MACE (HR: 0.72, 95% CI: 0.56-0.92), and major bleeding (HR: 0.66, 95% CI: 0.48-0.92). NOACs were more beneficial than warfarin for mortality, MACE and major bleeding in frail patients. The risk of clinical events associated with older patients was primarily seen in Europe and Asia (p-interaction > 0.05), but the effectiveness and safety of NOACs vs. warfarin was consistent across regions. CONCLUSIONS: Older age was independently associated with higher risk of death, major bleeding, TE and MACE. Compared with VKA, NOACs show improved effectiveness and safety in the older and patients with frailty, with similar efficacy across regions and ethnic groups.

来源:Age Ageing,查看原文。版权归原作者所有。

引用

  1. Liu H, Chen Y, Huang B, et al. Long-term clinical outcomes of oral anticoagulation in the older patients with atrial fibrillation aged ≥80 years: a report from the GLORIA-AF registry phase III. Age Ageing. 2025. PMID: 40462483. doi:10.1093/ageing/afaf139

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。